We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
151
Eledon Pharmaceuticals
ELDN
$314M
$40.3K 0.03%
14,855
– –
QURE icon
152
CALL
uniQure
QURE
$2.77B
$37.9K 0.03%
239
-115
-32% -$1.55K
SLS icon
153
CALL
SELLAS Life Sciences
SLS
$2.59B
$36.4K 0.03%
+920
New +$1.41K
RLAY icon
154
Relay Therapeutics
RLAY
$4.34B
$35.6K 0.03%
10,280
-90,204
-90% -$268K
TERN
155
CALL
DELISTED
Terns Pharmaceuticals
TERN
$35.3K 0.03%
+373
New +$1.17K
ELEV
156
DELISTED
Elevation Oncology
ELEV
$30.6K 0.02%
+83,416
New +$27.8K
SMMT icon
157
PUT
Summit Therapeutics
SMMT
$10.7B
$30.5K 0.02%
+873
New +$19.9K
ZLAB icon
158
Zai Lab
ZLAB
$2.28B
$30.5K 0.02%
+873
New +$28.7K
PRTC
159
DELISTED
PureTech Health
PRTC
$29.1K 0.02%
+1,685
New +$29.7K
GE icon
160
CALL
GE Aerospace
GE
$364B
$28.9K 0.02%
+40
New +$8.78K
OEF icon
161
PUT
iShares S&P 100 ETF
OEF
$20.1B
$27.5K 0.02%
+128
New +$35.7K
MRNA icon
162
CALL
Moderna
MRNA
$24.5B
$25.7K 0.02%
249
+115
+86% +$3.03K
BHVN icon
163
CALL
Biohaven
BHVN
$2.32B
$24.3K 0.02%
+230
New +$4.1K
CRDF icon
164
CALL
Cardiff Oncology
CRDF
$60.2M
$20.5K 0.02%
479
– –
ABR icon
165
CALL
Arbor Realty Trust
ABR
$996M
$19.5K 0.01%
+303
New +$3.19K
PFE icon
166
CALL
Pfizer
PFE
$143B
$18.2K 0.01%
462
-1,623
-78% -$37.9K
MNKD icon
167
CALL
MannKind Corp
MNKD
$1.25B
$18K 0.01%
1,197
– –
ORCL icon
168
CALL
Oracle
ORCL
$364B
$12.4K 0.01%
+100
New +$16.1K
FOLD
169
CALL
DELISTED
Amicus Therapeutics
FOLD
$11.1K 0.01%
303
– –
SOFI icon
170
CALL
SoFi Technologies
SOFI
$22.2B
$10.5K 0.01%
+200
New +$2.64K
NKTR icon
171
CALL
Nektar Therapeutics
NKTR
$2.31B
$8.67K 0.01%
1,560
+1,456
+1,400% +$16.3K
SMMT icon
172
Summit Therapeutics
SMMT
$10.7B
$7.04K 0.01%
+331
New +$7.55K
COGT icon
173
CALL
Cogent Biosciences
COGT
$6.68B
$6.25K ﹤0.01%
+16
New +$89
PRTA icon
174
CALL
Prothena Corp
PRTA
$453M
$4.59K ﹤0.01%
+230
New +$1.73K
NVO
175
CALL
Novo Nordisk
NVO
$223B
$3.94K ﹤0.01%
231
-20
-8% -$1.36K
5 6
7
8 9

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.